loading page

A long-term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non-squamous non-small cell lung cancer
  • +7
  • Makoto Furugen,
  • Daisuke Shibahara,
  • Tomo Kiyuna,
  • Wakaki Kami,
  • Kazuya Miyagi,
  • Shusaku Haranaga,
  • Toru Kubota,
  • Hirofumi Matsumoto,
  • Naoki Yoshimi,
  • Jiro Fujita
Makoto Furugen
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Daisuke Shibahara
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Tomo Kiyuna
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Wakaki Kami
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Kazuya Miyagi
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Shusaku Haranaga
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile
Toru Kubota
Author Profile
Hirofumi Matsumoto
Nakagami Hospital
Author Profile
Naoki Yoshimi
Okinawa Red Cross Hospital
Author Profile
Jiro Fujita
University of the Ryukyus Faculty of Medicine Graduate School of Medicine
Author Profile

Abstract

Molecular targeted drugs and immune checkpoint blockades are not indicated for all advanced non-small cell lung cancer (NSCLC) cases. For such patients, cytotoxic drugs are the main treatment, and the prognosis remains poor. We present a valuable case of advanced NSCLC that was potentially permanent cured by pemetrexed maintenance chemotherapy.

Peer review status:POSTED

02 Sep 2020Submitted to Clinical Case Reports
03 Sep 2020Assigned to Editor
03 Sep 2020Submission Checks Completed